Celcuity Inc.(CELC)

Biotechnology · Minneapolis, MN

$71.26-2.36 (-3.21%)

Delayed quote: Oct 6, 2026, 3:10 PM EDT

EV/FCF Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T19:11:12.516Z.

Stored calculation inputs

Calculation as of: 2026-10-06T19:11:12.516Z.

Quote observation: 2026-10-06T19:10:16.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 3,475,085,787
Total debt · period ending 2026-06-30: 754,385,000
Cash · period ending 2026-06-30: 182,049,000
TTM free cash flow · period ending 2026-06-30: -192,156,000

FMP input reference: bae8dd55c1776b4784265b7d6b815fecf0da21712464e51122872d0292d60ac3

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

CELC EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

CELC Competitors' EV/FCF Ratio

CELC

Celcuity Inc.

Current

Market Cap

$3.48B

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IDYA

IDEAYA Biosciences, Inc.

vs CELC

Market Cap

$3.46B

EV/FCF Ratio

N/A

TTM Avg

10.34x

3Y Avg

10.32x

5Y Avg

10.32x

XENE

Xenon Pharmaceuticals Inc.

vs CELC

Market Cap

$3.50B

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PLSE

Pulse Biosciences, Inc.

vs CELC

Market Cap

$3.44B

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

VCYT

Veracyte, Inc.

vs CELC

Market Cap

$3.54B

EV/FCF Ratio

19.83x

TTM Avg

25.47x

3Y Avg

39.59x

5Y Avg

56.23x

TNGX

Tango Therapeutics, Inc.

vs CELC

Market Cap

$3.54B

EV/FCF Ratio

N/A

TTM Avg

14.36x

3Y Avg

14.36x

5Y Avg

14.36x

IRTC

iRhythm Technologies, Inc.

vs CELC

Market Cap

$3.54B

EV/FCF Ratio

103.25x

TTM Avg

176.05x

3Y Avg

209.85x

5Y Avg

209.85x

ACAD

Acadia Pharmaceuticals Inc.

vs CELC

Market Cap

$3.39B

EV/FCF Ratio

17.64x

TTM Avg

24.95x

3Y Avg

51.13x

5Y Avg

51.13x

PBLS

Parabilis Medicines, Inc.

vs CELC

Market Cap

$3.34B

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CDNA

CareDx, Inc

vs CELC

Market Cap

$3.34B

EV/FCF Ratio

35.08x

TTM Avg

28.10x

3Y Avg

179.80x

5Y Avg

179.80x

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
Celcuity Inc. (CELC)	$3.48B	N/A	N/A	N/A	N/A
IDEAYA Biosciences, Inc. (IDYA)vs ›	$3.46B	N/A	10.34x	10.32x	10.32x
Xenon Pharmaceuticals Inc. (XENE)vs ›	$3.50B	N/A	N/A	N/A	N/A
Pulse Biosciences, Inc. (PLSE)vs ›	$3.44B	N/A	N/A	N/A	N/A
Veracyte, Inc. (VCYT)vs ›	$3.54B	19.83x	25.47x	39.59x	56.23x
Tango Therapeutics, Inc. (TNGX)vs ›	$3.54B	N/A	14.36x	14.36x	14.36x
iRhythm Technologies, Inc. (IRTC)vs ›	$3.54B	103.25x	176.05x	209.85x	209.85x
Acadia Pharmaceuticals Inc. (ACAD)vs ›	$3.39B	17.64x	24.95x	51.13x	51.13x
Parabilis Medicines, Inc. (PBLS)vs ›	$3.34B	N/A	N/A	N/A	N/A
CareDx, Inc (CDNA)vs ›	$3.34B	35.08x	28.10x	179.80x	179.80x

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/FCF Ratio: N/A

CELC EV/FCF Ratio Metrics

CELC Competitors' EV/FCF Ratio

Cash Flow Valuation Comparison

EV/FCF Ratio Formula & Definition

Related Metrics